Masoud H Manjili

Title: Masoud H Manjili: Innovator in Cancer and Infectious Disease Treatment

Introduction

Masoud H Manjili is a notable inventor based in Williamsville, NY (US). He has made significant contributions to the field of pharmaceutical compositions aimed at the prevention and treatment of cancer and infectious diseases. With a total of two patents to his name, his work is recognized for its innovative approach to addressing critical health challenges.

Latest Patents

Masoud H Manjili's latest patents focus on stress protein compositions and methods for the prevention and treatment of cancer and infectious diseases. These pharmaceutical compositions comprise a stress protein complex, which includes an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide can be associated with either cancer or an infectious disease. Preferred immunogenic polypeptides in his patents include gp100, her2/neu ECD-PD, and ICD antigens. The pharmaceutical compositions developed through his research can be utilized for both the treatment and prevention of these serious health conditions.

Career Highlights

Masoud H Manjili is affiliated with Health Research, Inc., where he continues to advance his research and innovations. His work has garnered attention for its potential impact on improving patient outcomes in the fields of oncology and infectious disease management.

Collaborations

Throughout his career, Masoud has collaborated with esteemed colleagues, including John R Subjeck and Robert A Henderson. These partnerships have contributed to the development and refinement of his innovative approaches to health challenges.

Conclusion

Masoud H Manjili stands out as a dedicated inventor whose work in stress protein compositions has the potential to revolutionize the treatment and prevention of cancer and infectious diseases. His contributions to the field are invaluable and reflect a commitment to improving health outcomes for patients worldwide.